Literature DB >> 3332177

Legionnaires' disease after bone marrow transplantation.

J Meletis1, G Arlet, E Dournon, S Pol, A Devergie, C Sportes, M N Peraldi, C Mayaud, Y Perol, E Gluckman.   

Abstract

Four patients developed legionnaires' disease after bone marrow transplantation. Two cases occurred early after transplant and were considered as part of a hospital epidemic due to contamination of water supply. The other two cases were considered to be sporadic because they occurred 3-4 weeks after hospital discharge. The outcome was good in two patients. In the third patient, recurrent disease was probably due to acquired resistance to macrolides, and complete cure was achieved after treatment with pefloxacin and rifampicin. The fourth patient died of overwhelming infection despite early treatment with erythromycin and pefloxacin. During the same period we treated 14 patients with pefloxacin for prevention of bacterial infection, of whom none developed Legionella pneumophila infection, while three of the patients reported here were in a group of 11 patients who received only oral non-absorbable antibiotics for gut decontamination. The fourth patient in this report was receiving no antibiotics. Thus pefloxacin seems to be effective as prophylaxis against L. pneumophila infection. When the hospital water supply was heated to 60 degrees C and chlorinated, the nosocomial cases in the hospital completely disappeared.

Entities:  

Mesh:

Year:  1987        PMID: 3332177

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

Review 1.  Diagnostic strategy in cancer patients with acute respiratory failure.

Authors:  Elie Azoulay; Benoît Schlemmer
Journal:  Intensive Care Med       Date:  2006-04-29       Impact factor: 17.440

2.  Improved survival of critically ill cancer patients with septic shock.

Authors:  Jérôme Larché; Elie Azoulay; Fabienne Fieux; Laurent Mesnard; Delphine Moreau; Guillaume Thiery; Michaël Darmon; Jean-Roger Le Gall; Benoît Schlemmer
Journal:  Intensive Care Med       Date:  2003-09-12       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.